Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Relapsed Advanced NSCLC After EGFR-TKI Failure (CTONG 0805)
NCT00922584Phase 2Completed
- Sponsor
- Chinese Society of Lung Cancer
- Start
- Dec 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in non-small cell lung cancer (NSCLC), sponsored by Chinese Society of Lung Cancer. Primary endpoint: Disease Control Rate at 1 year. Started Dec 2008; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00922584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00922584.